DaVita's international expansion into Brazil, Ecuador, Chile, and Colombia is expected to support long-term growth, complementing its defensive business model and leading 35% market share. While Q1 results showed mixed performance with strong international revenue growth offset by lower volumes and margins, management reaffirmed full-year guidance despite anticipating a Q2 impact from a cyber attack. The company's stock offers a 10% FCF yield, coupled with a decreasing share count due to buybacks, presenting a potential opportunity for investors.
DaVita (DVA) is strategically expanding its international presence with new clinics in Brazil, Ecuador, Chile, and Colombia, aiming to secure long-term growth beyond the U.S. market, where it currently commands a 35% market share in an oligopolistic setting. The company's defensive business model, providing mission-critical services to over 280,000 patients, is expected to support revenue growth above inflation. Financially, DaVita offers an attractive 10% free cash flow (FCF) yield, complemented by a rapidly decreasing share count driven by active share buybacks. First-quarter results presented a mixed picture, with strong international revenue growth partially offset by lower domestic volumes and margins. Despite an anticipated impact on second-quarter results from a cyber attack in April, management has reaffirmed its full-year guidance, signaling confidence in its operational resilience and long-term strategy.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.70
Ticker Sentiment